TOKYO, JAPAN - Medical & Biological Laboratories Co., Ltd. (President: Kimimasa Yamada) released the SARS-CoV-2 antigen test kit "GLINE-2019-nCoV Ag kit", which was approved for manufacturing and marketing in Japan on February 10, 2022. We donated 20,000 kits to Ina City, Nagano Prefecture, where our research and production facilities are located.
On March 3, 2022, Kimimasa Yamada, President and CEO of MBL, donated 20,000 kits of SARS-CoV-2 antigen test kit "GLINE-2019-nCoV Ag kit" to Ina City. He received a letter of appreciation from Mayor Shirotori.
Contact details
-
Download vCard
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
MEBGEN™ BRAF 2 Kit Receives MHLW Approval as a Companion Diagnostic for Use with Patients with Thyroid Cancer
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of...
Notice of Approval for First-Class Marketing License for Medical Devices
With the acquisition of the First-Class Marketing License for Medical Devices, MBL will be able to market highly controlled medical devices, including genetic testing systems using NGS.
Launch of a New Chemiluminescence Immunoassay Analyzer “iStar500”
The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact & integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency ...
MEBGEN™ BRAF 3 Kit Receives MHLW Approval and Insurance Coverage as a Tumor Agnostic Companion Diagnostic
With MHLW approval and insurance coverage, the MEBGEN™ BRAF 3 Kit is expected to support personalized medicine based on its ability to detect the presence or absence of BRAF gene mutations in rare ...
New Antibody Development for Use in Drug Delivery to Motor Nerves
MBL raised and delivered monoclonal antibodies for Jiksak Bioengineering, a startup company with proprietary technologies developed for new therapeutic innovation in motor neuron degenerative disea...